Sign In
Last checked at 
23 Dec 2011 07:00
Press Release | 23 December 2011 |
Evocutis plc
("the Company")
Director's Dealing
Evocutis plc (AIM:EVO), the speciality pharmaceutical research and development company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, has today been notified that, on 22 December 2011, Tom Bannatyne, Chairman of the Company, acquired 750,000 ordinary shares of 1p each in the Company, at a price of 2.625p per share. Following this purchase Mr Bannatyne has a beneficial interest in 14,714,670 ordinary shares representing approximately 8.50 per cent. of the Company's issued share capital.
- Ends -
For further information, please contact:
Evocutis plc |
| |
Dr Stephen Jones, Chief Executive Officer | +44 (0)845 125 9204 |
|
Tom Bannatyne, Chairman |
| |
Zeus Capital ltd | ||
Tom Rowley/Andrew Jones | Tel: +44(0)161 831 1512 | |
www.zeuscapital.co.uk | ||
XCAP Securities plc | |
Karen Kelly/John Grant | Tel: +44(0) 207 101 7070 |
www.xcapgroup.co.uk |
Media enquiries:
Abchurch Communications | |
Adam Michael/ Jamie Hooper | Tel: +44 (0) 20 7398 7719 |
jamie.hooper@abchurch-group.com | www.abchurch-group.com |
Notes to editors
About Evocutis plc
With a rich portfolio of new product opportunities Evocutis offers antimicrobial expertise to the cosmetic, consumer healthcare and pharmaceutical industries.
Additionally, Evocutis is uniquely able to combine research for laboratory testing, advanced skin models and clinical testing to offer a complete service for the development of skin care products and ingredients. Through research and testing we enable our clients to advance the discovery of skin care products that actually work.
Evocutis works with companies at all stages of the product development pipeline offering R&D solutions from ownable technology platforms through to tailored research, and now provides an independent commercial testing facility to the pharmaceutical and healthcare industries. Unique characteristics of its colonised full thickness model of human skin (LabSkinTM) allow rapid, cost effective screening of, for example, anti-aging, anti-inflammatory and antimicrobial ingredients and products for use on skin.
Evocutis also offers high quality contract research services specialising in Human Skin Microbiology, tissue culture systems and Human Volunteer and Clinical Dermatology Research.
When it comes to topical antimicrobial innovation the Evocutis focus is simple: intelligent and specialised R&D input.
For further information, please see www.evocutis.com.
Follow the stocks
